Associated tags: Cancer, Biotechnology, BCT, TSX, Therapy, Patient, Pharmaceutical industry, Survival, Immunotherapy, Breast cancer
Locations: CANADA, TX, SG, WEST VANCOUVER, BC, CA, CHICAGO, BRITISH COLUMBIA, IL, III, CORTES, BRIA, AM, BARDIA
Retrieved on:
Wednesday, April 24, 2024
Wilfrid Sellars,
University,
Mayo Clinic,
Weill Cornell Medicine,
University of Miami,
Poster,
BCT,
MD,
TSX,
Principal investigator,
Doctor of Philosophy,
Spacecraft,
UPMC,
McCormick Place,
DRS,
ASCO,
Cornell University,
ADC,
Patient,
Society,
Annual general meeting,
Therapy,
Partner,
Pharmaceutical industry Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MD
Key Points:
- Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MD
Two poster presentations include Drs.
- Principal Investigator and Professor of Oncology, Mayo Clinic, Saranya Chumsri, MD, will be giving the presentation.
- BriaCell will also have two poster presentations.
- The first poster will describe the Company’s ongoing pivotal Phase 3 registrational study in advanced metastatic breast cancer.
Retrieved on:
Wednesday, April 10, 2024
Breast cancer,
Cancer,
Poster,
HLA,
Cytokine,
BCT,
Immunotherapy,
Breast,
TSX,
Doctor of Philosophy,
GM-CSF,
Prostate cancer,
Patient,
AACR,
Immune system,
GMP,
B cell,
Therapy,
NK,
Vaccine “We anticipate that our novel immunotherapeutic platform will provide potent and long-lasting anti-cancer activity in cancer patients.
Key Points:
- “We anticipate that our novel immunotherapeutic platform will provide potent and long-lasting anti-cancer activity in cancer patients.
- “We have successfully enhanced antigen presentation activity and cytokine expression while expanding our HLA target range to cover nearly 99% of the population.
- BriaCell has designed Bria-OTS+™, an immunotherapy platform representing the next generation (enhanced version) of Bria-OTS™, BriaCell’s personalized off-the-shelf (i.e.
- BriaCell expects to use Bria-OTS+™ and Bria-PROS+™ in its upcoming phase 1/2a clinical studies for breast and prostate cancer, respectively.
HER2,
ILD,
CPI,
Survival,
Progression-free survival,
Central nervous system,
Patient,
CNS,
History,
Death,
Eribulin,
Spacecraft,
MD,
CBR,
TPC,
EMBRACE,
Life,
BCT,
AACR,
TSX,
Therapy,
Breast cancer,
Safety,
Poster,
CMO,
PFS,
ADC,
PD-1,
Pharmaceutical industry “ADCs are the latest treatments for very difficult-to-treat advanced metastatic breast cancer.
Key Points:
- “ADCs are the latest treatments for very difficult-to-treat advanced metastatic breast cancer.
- To our knowledge, there are no effective treatment options in this patient population for whom the progression-free survival prognosis is only a few weeks.
- BriaCell will be monitoring ADC resistant patients in its ongoing pivotal Phase 3 study of Bria-IMT™ and CPI in advanced metastatic breast cancer.
- Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomized study.
Master of Science,
Breast cancer,
BCT,
Division,
CMO,
Doctor of Philosophy,
MD,
University,
Quality of life,
TSX,
Letter,
Vaccine,
Breast,
MD Anderson Cancer Center,
Cancer,
Therapy,
Associate professor,
Patient,
Survival,
Disease,
Prostate cancer,
Pharmaceutical industry Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer), BriaCell’s novel off-the-shelf personalized cancer vaccines, marks a major milestone for BriaCell
Key Points:
- Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer), BriaCell’s novel off-the-shelf personalized cancer vaccines, marks a major milestone for BriaCell
PHILADELPHIA and VANCOUVER, British Columbia, March 07, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that it has received and executed a letter of intent with Paula Pohlmann, MD, MSc, PhD, Associate Professor, Department of Investigational Cancer Therapeutics and Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX to advance the clinical development of Bria-OTS+ and Bria-PROS+, BriaCell’s personalized off-the-shelf cellular cancer vaccines in advanced breast cancer and prostate cancer, respectively.
- “We are ecstatic about working with the team led by Dr. Pohlmann,” stated Dr. Williams, BriaCell’s President & CEO.
- “We strongly believe in the therapeutic potential of our novel personalized next-generation vaccine platform and this agreement will be invaluable to us as we advance the clinical development of our off-the-shelf therapies to those cancer patients with persistent unmet medical needs.”
“Through this agreement, we expect to further our understanding of our novel immunotherapy’s mechanism of action and its use in breast and prostate cancer patients,” stated Dr. Giuseppe Del Priore, BriaCell’s CMO.
- “Our shared goal is to improve the survival and quality of life in cancer patients who are fighting a disease with a poor prognosis and a short life expectancy.”
PHILADELPHIA and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting three posters at the 2024 American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10 at San Diego Convention Center, San Diego, CA.
Key Points:
- PHILADELPHIA and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting three posters at the 2024 American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10 at San Diego Convention Center, San Diego, CA.
- The details are listed below.
Retrieved on:
Tuesday, February 27, 2024
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, provides an update to the previously announced investigation of alleged illegal trading activity of its publicly traded securities.
Key Points:
- PHILADELPHIA and VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, provides an update to the previously announced investigation of alleged illegal trading activity of its publicly traded securities.
- Upon external forensic analysis of data from various industry sources consistently demonstrating significant settlement share imbalances, and after discussions with 12 individual prime brokers for clarification of these imbalances, the Company has filed formal complaints with the Financial Industry Regulatory Authority (FINRA) and the Canadian Investment Regulatory Organization (CIRO).
- The Company will continue to work with regulatory authorities to combat illegal manipulative trading activities and will provide further updates on this investigation as they become available.
Retrieved on:
Wednesday, February 7, 2024
Survival,
Breast cancer,
PFS,
Literature,
Patient,
Pain,
TSX,
ADC,
Therapy,
Quality of life,
HLA,
Spacecraft,
Liver disease,
Liver,
BCT,
ILD,
Pharmaceutical industry exhibited clinical outcomes) Phase 2 advanced breast cancer patients treated with BriaCell’s Bria-IMT™ regimen – the same formulation being used in BriaCell’s open pivotal Phase 3 study.
Key Points:
- exhibited clinical outcomes) Phase 2 advanced breast cancer patients treated with BriaCell’s Bria-IMT™ regimen – the same formulation being used in BriaCell’s open pivotal Phase 3 study.
- Additionally, a disease control rate of 50% was reported in similarly treated evaluable patients who had failed prior antibody-drug conjugate (ADC) therapy.
- “This data provides further encouragement to us as we continue our pivotal Phase 3 study enrollment.
- No cases of Interstitial Lung Disease (ILD) with Bria-IMT™ (a well-documented serious side effect of ADCs) reported in this group of patients.
Retrieved on:
Tuesday, February 6, 2024
Prostate cancer,
Investigational New Drug,
Cytokine,
Immunotherapy,
SITC,
Clinical trial,
NK,
Society,
Patient,
IND,
Good,
Death,
TSX,
Allele,
NKT,
Therapy,
Vaccine,
Good manufacturing practice,
HLA,
Cancer,
GMP,
BCT We are enthusiastic about commencing GMP manufacturing for our prostate cancer clinical candidate, continuing our efforts at transforming targeted cancer therapy via the introduction of potent personalized cellular cancer vaccines,” stated Dr. William V. Williams, BriaCell’s President and CEO.
Key Points:
- We are enthusiastic about commencing GMP manufacturing for our prostate cancer clinical candidate, continuing our efforts at transforming targeted cancer therapy via the introduction of potent personalized cellular cancer vaccines,” stated Dr. William V. Williams, BriaCell’s President and CEO.
- “The successful development of this first candidate showcases our capacity to create novel cancer immunotherapies and advance them towards clinical application.
- BriaCell genetically engineers cancer cell lines to produce cytokines and co-stimulatory factors that significantly increase immune stimulation compared to the unmodified (parent) cancer cell lines.
- According to 2024 Cancer Facts & Figures , prostate cancer is projected to be the most common cancer among men in 2024.
Retrieved on:
Wednesday, January 31, 2024
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the “Shareholders”) for the year ended July 31, 2023 held on January 30, 2024 (the “Meeting”).
Key Points:
- PHILADELPHIA and VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the “Shareholders”) for the year ended July 31, 2023 held on January 30, 2024 (the “Meeting”).
- A total of 5,375,071 common shares of the Company (the “Common Shares”) were voted, representing 33.63% of the Company’s issued and outstanding Common Shares.
- Gross, Dr. Rebecca Taub, Mr. Vaughn C. Embro-Pantalony, and Mr. Martin E. Schmieg as directors of the Company.
- A total of 5,375,071 common shares were voted in connection with the election of the directors as follows:
Retrieved on:
Thursday, January 4, 2024
MRI,
Neoplasm,
Breast cancer,
Woman,
BCT,
Eye,
Therapy,
CNS,
TSX,
Patient,
Central nervous system,
Magnetic resonance imaging,
Exophthalmos,
Medical imaging The patient had metastatic breast cancer behind her eye, causing proptosis (eye-bulging) and significant pain that were both markedly reduced with BriaCell’s treatment.
Key Points:
- The patient had metastatic breast cancer behind her eye, causing proptosis (eye-bulging) and significant pain that were both markedly reduced with BriaCell’s treatment.
- We observed significant tumor reduction along with significant eye pain reduction after only 3 cycles of treatment with the Bria-IMT™ combination regimen.
- The Bria-IMT™ regimen has been very well tolerated and the patient remains on treatment,” stated Dr. William V. Williams, BriaCell’s President and CEO.
- The Bria-IMT™ combination regimen is currently undergoing a pivotal Phase 3 study in advanced breast cancer.
